Vaxcyte, Inc.
$46.93
-0.57%Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company also develops VAX-XP to protect against emerging strains and address antibiotic resistance; VAX-A1, a conjugate vaccine candidate designed to treat Group A Strep; and VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.
At a Glance
Live SnapshotIntrinsic Alpha Methodology
Thesis Lenses
Signal
Medium confidenceValuation multiple is compressed (P/E -8.3).
Valuation inputs: P/E -8.3, earnings yield N/A, momentum -0.6%.
If multiples stay elevated while momentum fades, downside repricing risk rises.
Driver
High confidenceReturn profile is soft (ROE -28.5%, ROIC -32.5%).
Profitability stack: net margin 0.0%, ROE -28.5%, ROIC -32.5%.
Quality deterioration often appears in margins before it shows up in headline EPS.
Risk
High confidenceRisk profile is balanced but has notable pressure points to monitor.
Risk factors: liabilities/assets +11.8%, momentum -0.6%, net margin 0.0%.
Higher leverage with weak momentum and thin margins can amplify drawdown severity.
Vaxcyte, Inc. Market vs Earnings Trajectory
Loading price and EPS data...
Vaxcyte, Inc. Fair Value Envelope
No Revenue Data
PCVX has not reported any revenue values in the available annual periods.
Vaxcyte, Inc. Profit Bridge
Profitability Analysis
No Gross Profit Margin Data
PCVX has not reported any gross profit margin values in the available annual periods.
No Operating Profit Margin Data
PCVX has not reported any operating profit margin values in the available annual periods.
No Net Profit Margin Data
PCVX has not reported any net profit margin values in the available annual periods.
Vaxcyte, Inc. Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Strong cash conversion. Most reported earnings translate into actual cash flow, suggesting solid fundamentals.
CapEx Intensity
Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.
FCF Growth Trend
Significant FCF decline raises concerns. Urgent review needed of operational performance and capital allocation.
Working Capital Impact
Working capital inflow boosted cash flow. Efficient management of receivables, inventory, and payables contributing positively.
Vaxcyte, Inc. Funding & Solvency Profile
Financial Health Analysis
Current Ratio
Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.
Debt-to-Equity Ratio
Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.
Working Capital
Strong working capital position provides significant operational flexibility and financial cushion.
Asset Composition
Balanced asset mix between current and non-current assets, typical of many stable businesses.
Financial Health Insight
Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.
Vaxcyte, Inc. Street Expectations Map
Wall Street analysts project that PCVX stock may rise significantly over the coming 12 months. The consensus 1-year price target stands at 89.00, with estimates ranging from a low of 89.00 to a high of 89.00.
The consensus 1-year price target stands at 89.00, with estimates ranging from a low of 89.00 to a high of 89.00.
Analyst Consensus Analysis
Upside Potential
Substantial upside potential. Analysts see significant value gap, suggesting the stock may be materially undervalued at current levels.
Analyst Agreement
High analyst agreement. Narrow target range indicates strong consensus on valuation, suggesting clear investment thesis and predictable outlook.
Analyst Conviction
Strong buy conviction: High upside with tight consensus suggests compelling investment opportunity backed by analyst confidence.
Market Sentiment Insight
Rare opportunity: Exceptional upside potential with strong analyst consensus creates a compelling setup. The combination of significant price target premium and tight agreement suggests high-conviction undervaluation that may attract institutional capital.
Vaxcyte, Inc. Insider Positioning
During the last 12 months, insiders have sold $1.45M worth of PCVX shares, with no buying activity reported.
3 Months
0
0.00
13.1K
760.33K
-760K
-$760K
3-6 Months
0
0.00
14.7K
689.93K
-690K
-$690K
6-9 Months
0
0.00
0
0.00
+0
+$0
9-12 Months
0
0.00
0
0.00
+0
+$0
Top Buyers
No buying activity
Top Sellers
Cowan Elvia
Officer: Svp, Finance & Cao
$644K
Dhaliwal Harpreet S.
Officer: Chief Technical Ops Officer
$455K
Wassil Jim
Officer: Chief Operating Officer
$351K
Insider Activity Analysis
Net Insider Sentiment
Strong bearish signal with $1.45M net selling. Heavy insider selling may indicate concerns about valuation or near-term prospects.
Buy/Sell Ratio
Very poor ratio. Heavy selling with minimal buying suggests insiders may be concerned about valuation or outlook.
Recent Trend (3 Months)
Heavy recent selling activity. Recent insider sales notably exceed purchases—may warrant investigation into company developments.
Insider Participation
3 insider sellers vs. 0 buyers. Widespread selling across multiple insiders may signal concerns.
Insider Activity Insight
Multiple red flags: Heavy selling, numerous sellers, and continued recent selling create a concerning pattern. Investigate fundamental drivers and consider whether company guidance or industry conditions have deteriorated.
pcvx Dividend History
Learning Layer
Related Guides
Build conviction on PCVX by pairing this stock hub with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.